Verrica Pharmaceuticals, Inc. (VRCA)
Levi & Korsinsky, LLP announces that a VRCA class action lawsuit has been filed on behalf of investors who purchased Verrica Pharmaceuticals, Inc. (VRCA) securities between May 28, 2021 and May 24, 2022. For more on the VRCA Lawsuit please contact us today.
According to the Verrica Pharmaceuticals, Inc. lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that:
(1) there were manufacturing deficiencies at the facility where Verrica’s contract manufacturer produced a bulk solution for the Company’s lead product candidate, VP-102; (2) these deficiencies were not remediated when Verrica resubmitted its New Drug Application for VP-12 for molluscum; (3) the foregoing presented significant risks to Verrica obtaining regulatory approval of VP-102 for molluscum; and (4) as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
If you suffered a loss in Verrica Pharmaceuticals, Inc. you have until August 5, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Deadline of Submission is Until August 5, 2022
Verrica Pharmaceuticals, Inc. Class Action Lawsuit
Verrica Pharmaceuticals, Inc. Lawsuit
VRCA Class Action Lawsuit
Verrica Pharmaceuticals, Inc. (VRCA) Class Action Lawsuit